
<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Clinova</title>
	<atom:link href="http://clinova.co.uk/feed/" rel="self" type="application/rss+xml" />
	<link>http://clinova.co.uk</link>
	<description>Just another WordPress weblog</description>
	<lastBuildDate>Tue, 09 Mar 2010 19:09:14 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Clinova in Korea</title>
		<link>http://clinova.co.uk/clinova-in-korea/</link>
		<comments>http://clinova.co.uk/clinova-in-korea/#comments</comments>
		<pubDate>Tue, 09 Mar 2010 19:05:41 +0000</pubDate>
		<dc:creator>clinovaadmin</dc:creator>
				<category><![CDATA[Updates]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=650</guid>
		<description><![CDATA[Clinova’s Director of Research and Development, Arsalan Karim is in Seoul, Korea presenting an overview of the current and future pharmaceutical and consumer health products that Clinova is developing.
For more information contact info@clinova.co.uk
]]></description>
			<content:encoded><![CDATA[<p>Clinova’s Director of Research and Development, Arsalan Karim is in Seoul, Korea presenting an overview of the current and future pharmaceutical and consumer health products that Clinova is developing.</p>
<p>For more information contact info@clinova.co.uk</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/clinova-in-korea/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinova in Japan</title>
		<link>http://clinova.co.uk/clinova-in-japan/</link>
		<comments>http://clinova.co.uk/clinova-in-japan/#comments</comments>
		<pubDate>Tue, 09 Mar 2010 18:54:01 +0000</pubDate>
		<dc:creator>clinovaadmin</dc:creator>
				<category><![CDATA[Updates]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=646</guid>
		<description><![CDATA[Clinova’s Director of Research and Development, Arsalan Karim is in Japan presenting an overview of the current and future pharmaceutical and consumer health products that Clinova is developing. Arsalan Karim has presented to over 200 Japanese pharmaceutical companies during the course of his visit on:
1st of March at 1410 New Hall, British Embassy, Tokyo
4th of March at [...]]]></description>
			<content:encoded><![CDATA[<p>Clinova’s Director of Research and Development, Arsalan Karim is in Japan presenting an overview of the current and future pharmaceutical and consumer health products that Clinova is developing. Arsalan Karim has presented to over 200 Japanese pharmaceutical companies during the course of his visit on:</p>
<p>1<sup>st</sup> of March at 1410 New Hall, British Embassy, Tokyo</p>
<p>4<sup>th</sup> of March at the Ball Room, Ritz-Carlton Hotel, Ossaka</p>
<p>Arsalan is still in the region and interested companies in Japan are advised to make contact with Clinova.</p>
<p>For further information, please email, <a href="mailto:Info@clinova.co.uk">Info@clinova.co.uk</a></p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/clinova-in-japan/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>SWINE FLU:  Filtering fact from fiction about face masks</title>
		<link>http://clinova.co.uk/swine-flu-filtering-fact-from-fiction-about-face-masks/</link>
		<comments>http://clinova.co.uk/swine-flu-filtering-fact-from-fiction-about-face-masks/#comments</comments>
		<pubDate>Mon, 25 Jan 2010 17:37:16 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Press Release]]></category>

		<guid isPermaLink="false">http://clinova.co.uk/?p=576</guid>
		<description><![CDATA[“Face masks need filters to provide optimal protection from swine flu”
Download PDF Version
Southampton, UK: &#8211; People who want to take extra precautions against swine flu should look for masks with built-in filters, according to Dr Robin J Harman, a pharmaceutical and regulatory expert,  “There has been much debate about the benefits of wearing a mask [...]]]></description>
			<content:encoded><![CDATA[<h3 style="text-align: center;">“Face masks need filters to provide optimal protection from swine flu”</h3>
<p style="text-align: center;"><a href="http://clinova.co.uk/wp-content/uploads/2010/01/Clinova-Press-Release.pdf">Download PDF Version</a></p>
<p>Southampton, UK: &#8211; People who want to take extra precautions against swine flu should look for masks with built-in filters, according to Dr Robin J Harman, a pharmaceutical and regulatory expert,  “There has been much debate about the benefits of wearing a mask to prevent infection with swine flu.  Ordinary surgical masks provide some protection from airborne particles, but the UK Department of Health has stated that `basic face masks don’t protect people from becoming infected’.1 However, masks with built-n particle filters that are CE marked and meet the European Standard class FFP3 have efficiency of 99% or more.”   A filtering face piece (FFP3) device is a mask that provides a high level of filtering capability and face fit, and generates an effective barrier to both droplets and fine aerosols.</p>
<p>Swine flu virus is spread when miniscule droplets emitted by coughing and sneezing or deposited on hands and surfaces reach the nose or mouth.  If you block the particles from being inhaled, for example, with a mask with a built-in particle filter, you can help reduce your risks of becoming infected.</p>
<p>A scientific study has shown that 20-85% of virus particles can penetrate two ordinary types of surgical mask, and potentially expose the wearer to infection2.  But masks with FFP3 respirators, such as the Covaflu FFP3 face mask, will block more than 99% of airborne virus droplets that are 0.3 microns in size – the majority of swine flu-infected droplets will be larger than this.</p>
<p>UK manufacturer, Clinova, has seen a surge in demand in the past week for Covaflu FFP3 masks, which meet World Health Organisation and the UK Health and Safety Executive standards for use in influenza pandemics.  “Our Covaflu masks meet the highest criteria for preventing harmful particles entering the system, which could result in infection.  We have increased production significantly to meet demand and set up a special order form on our website, so that people who want to take extra measures to protect themselves in a pandemic will have access to the best possible protective masks,” said Jim Tremouliaris, Director of Clinova Ltd.</p>
<p>Covaflu FFP3 masks are available at all good pharmacies. They can be ordered online at www.clinova.co.uk or by telephoning 08452590175.</p>
<h5>Notes to Editors:</h5>
<p>The Health Protection Agency has advised that there are some circumstances where wearing a facemask may be beneficial:</p>
<ul>
<li>reducing the risk of passing on infection &#8211; people with flu wearing a facemask when they are in contact with other people; or</li>
<li>reducing the risk of getting an infection; healthy people wearing a facemask when they are caring for a patient with flu.</li>
</ul>
<p>The wearing of facemasks by healthy individuals who are not involved in caring for people who are ill (i.e. the general public) is not recommended by the HPA.  However, it is recognised that some people may choose to do so.</p>
<p>A filtering face piece (FFP3) device is a mask which is certified to the PPE Directive. It provides a high level of filtering capability and face fit. It can be supplied with an exhale valve so that it can be worn comfortably over a fairly long period of time. It will provide an effective barrier to both droplets and fine aerosols and is the type recommended particularly for people in the healthcare sector dealing with symptomatic patients undergoing treatment where aerosols are likely to be generated.  For instructions on appropriate fit and usage, please read the manufacturers enclosed information leaflet, supplied with the purchase of every mask.</p>
<p>Although wearing FFP3 respiratory face masks provides protection from airborne contamination, it does not guarantee full immunity against swine flu. The Department of Health advises that in the case of a flu pandemic, a combination of an FFP3 face mask, eye goggles and gloves should be used. In addition, unnecessary travel should be minimized or avoided, unless absolutely essential, and people should be wearing all the essential Personal Protection.<br />
Clinova Ltd is a pharmaceutical group focused on developing, manufacturing and marketing a broad range of pharmaceutical products and diagnostic devices. Clinova has its global headquarters in Southampton.</p>
<h5>References</h5>
<ul>
<li> Department of Health leaflet, 30 April 2009, Important information about swine fever.</li>
<li>Balazy A, Toivola M, Adhikari A. Am J Infect Control 2006:34, 51 – 57.</li>
</ul>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/swine-flu-filtering-fact-from-fiction-about-face-masks/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covaflu mask FFP2</title>
		<link>http://clinova.co.uk/covaflu-mask-ffp2/</link>
		<comments>http://clinova.co.uk/covaflu-mask-ffp2/#comments</comments>
		<pubDate>Fri, 15 Jan 2010 17:57:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Research]]></category>

		<guid isPermaLink="false">http://www.sumeetchawla.co.cc/?p=175</guid>
		<description><![CDATA[Clinova has developed Covaflu FFP2 disposable face masks to prevent harmful particles from entering your lungs by providing FFP2 particle filtration. Covaflu protects healthy individuals, by preventing person to person airborne contamination and filters out approximately 94% of droplets, which are 0.3 microns in size and over; the majority of sneezed droplets contaminated with influenza [...]]]></description>
			<content:encoded><![CDATA[<p>Clinova has developed Covaflu FFP2 disposable face masks to prevent harmful particles from entering your lungs by providing FFP2 particle filtration. Covaflu protects healthy individuals, by preventing person to person airborne contamination and filters out approximately 94% of droplets, which are 0.3 microns in size and over; the majority of sneezed droplets contaminated with influenza will be bigger in size than 0.3 microns. The folded design allows easy storage in the pocket. Clinova is currently marketing the product globally.</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/covaflu-mask-ffp2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covaflu mask FFP3</title>
		<link>http://clinova.co.uk/covaflu-mask-ffp3/</link>
		<comments>http://clinova.co.uk/covaflu-mask-ffp3/#comments</comments>
		<pubDate>Fri, 15 Jan 2010 17:54:49 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Research]]></category>

		<guid isPermaLink="false">http://www.sumeetchawla.co.cc/?p=173</guid>
		<description><![CDATA[Clinova has developed Covaflu FFP3 disposable face masks to prevent harmful particles from entering your lungs by providing FFP3 particle filtration. Covaflu protects healthy individuals, by preventing person to person airborne contamination and filters out approximately 99% of droplets, which are 0.3 microns in size and over; the majority of sneezed droplets contaminated with influenza [...]]]></description>
			<content:encoded><![CDATA[<p>Clinova has developed Covaflu FFP3 disposable face masks to prevent harmful particles from entering your lungs by providing FFP3 particle filtration. Covaflu protects healthy individuals, by preventing person to person airborne contamination and filters out approximately 99% of droplets, which are 0.3 microns in size and over; the majority of sneezed droplets contaminated with influenza will be bigger in size than 0.3 microns. The folded design allows easy storage in the pocket. Covaflu complies with the World Health Organisation (WHO) and Health Protection Agency (HPA) guidelines for the minimisation of risk against influenza infection (e.g.H1N1). Clinova is currently marketing the product globally and it is currently recognised as one of the leading respirators in the global market place.</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/covaflu-mask-ffp3/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quash</title>
		<link>http://clinova.co.uk/quash-2/</link>
		<comments>http://clinova.co.uk/quash-2/#comments</comments>
		<pubDate>Fri, 15 Jan 2010 17:53:09 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Research]]></category>

		<guid isPermaLink="false">http://www.sumeetchawla.co.cc/?p=171</guid>
		<description><![CDATA[Clinova has developed a patented formulation of 100% natural ingredients that has been proven in independent laboratory tests to kill 99.9% of common bacteria, viruses and fungi that can cause illness. The product also encapsulates vitamins and minerals to help moisturise and nourish your skin. Quash contains no alcohol or chemicals and has been tested [...]]]></description>
			<content:encoded><![CDATA[<p>Clinova has developed a patented formulation of 100% natural ingredients that has been proven in independent laboratory tests to kill 99.9% of common bacteria, viruses and fungi that can cause illness. The product also encapsulates vitamins and minerals to help moisturise and nourish your skin. Quash contains no alcohol or chemicals and has been tested in controlled laboratory tests to EN 14476: 2007. Quash is made from natural ingredients that work synergistically together to kill the toughest of germs and viruses. Clinova is currently marketing the product globally.</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/quash-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TBC</title>
		<link>http://clinova.co.uk/painkiller/</link>
		<comments>http://clinova.co.uk/painkiller/#comments</comments>
		<pubDate>Fri, 15 Jan 2010 17:50:56 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Research]]></category>

		<guid isPermaLink="false">http://www.sumeetchawla.co.cc/?p=168</guid>
		<description><![CDATA[We aim to produce a new generation compound encapsulating a Non-opioid analgesic to treat mild-to-moderate pain in a variety of medical conditions. Clinova is currently completing phase 3 studies of Clin3004 and we expect the candidate to progress to launch in early 2010.
]]></description>
			<content:encoded><![CDATA[<p>We aim to produce a new generation compound encapsulating a Non-opioid analgesic to treat mild-to-moderate pain in a variety of medical conditions. Clinova is currently completing phase 3 studies of Clin3004 and we expect the candidate to progress to launch in early 2010.</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/painkiller/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bacticure Cream</title>
		<link>http://clinova.co.uk/bacticure-cream/</link>
		<comments>http://clinova.co.uk/bacticure-cream/#comments</comments>
		<pubDate>Fri, 15 Jan 2010 17:31:41 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Research]]></category>

		<guid isPermaLink="false">http://www.sumeetchawla.co.cc/?p=165</guid>
		<description><![CDATA[In December 2009, Clinova launched Bacticure cream for the treatment of topical bacterial infections. The cream contains a combination of natural plant based ingredients. The product’s has a potent, broad spectrum antimicrobial activity. Clinova is currently marketing the product globally and expects to report strong sales for the product in 2010 and in 2011.
]]></description>
			<content:encoded><![CDATA[<p>In December 2009, Clinova launched Bacticure cream for the treatment of topical bacterial infections. The cream contains a combination of natural plant based ingredients. The product’s has a potent, broad spectrum antimicrobial activity. Clinova is currently marketing the product globally and expects to report strong sales for the product in 2010 and in 2011.</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/bacticure-cream/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TBC</title>
		<link>http://clinova.co.uk/dysmenorrheal-treatment/</link>
		<comments>http://clinova.co.uk/dysmenorrheal-treatment/#comments</comments>
		<pubDate>Fri, 15 Jan 2010 17:28:37 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Research]]></category>

		<guid isPermaLink="false">http://www.sumeetchawla.co.cc/?p=162</guid>
		<description><![CDATA[Clinova is developing a new generation antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, a molecule responsible for the degradation of fibrin. Our preliminary research indicates that Clin3006 could be used as first line non hormonal treatment of dysfunctional uterine bleeding, and heavy bleeding associated with uterine fibroids. Clinova is currently completing pre-clinical [...]]]></description>
			<content:encoded><![CDATA[<p>Clinova is developing a new generation antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, a molecule responsible for the degradation of fibrin. Our preliminary research indicates that Clin3006 could be used as first line non hormonal treatment of dysfunctional uterine bleeding, and heavy bleeding associated with uterine fibroids. Clinova is currently completing pre-clinical studies of Clin3006 and we expect the candidate to progress to phase 1 in early 2011.</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/dysmenorrheal-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TBC</title>
		<link>http://clinova.co.uk/antibacterial/</link>
		<comments>http://clinova.co.uk/antibacterial/#comments</comments>
		<pubDate>Fri, 15 Jan 2010 17:25:38 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Research]]></category>

		<guid isPermaLink="false">http://www.sumeetchawla.co.cc/?p=159</guid>
		<description><![CDATA[Clinova is developing a new generation antibiotic product for the treatment of infections caused by anaerobic bacteria and protozoa. It is a well-tolerated formulation and could become a valued treatment for a variety of bacterial infections. The company is validating a variety of formulations, which is undergoing pre-clinical development before entering clinical development.
]]></description>
			<content:encoded><![CDATA[<p>Clinova is developing a new generation antibiotic product for the treatment of infections caused by anaerobic bacteria and protozoa. It is a well-tolerated formulation and could become a valued treatment for a variety of bacterial infections. The company is validating a variety of formulations, which is undergoing pre-clinical development before entering clinical development.</p>
]]></content:encoded>
			<wfw:commentRss>http://clinova.co.uk/antibacterial/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
